AAAAAA

   
Results: 1-25 | 26-38
Results: 1-25/38
GEMCITABINE(G)- AN ACTIVE REGIMEN IN ADVANCED CELL-CARCINOMA (TCC) - AN NCIC STUDY( CISPLATIN (C) )
Authors: MOORE MJ TANNOCK I WINQUIST E TOLCHER A BENNETT K SEYMOUR L
Citation: Mj. Moore et al., GEMCITABINE(G)- AN ACTIVE REGIMEN IN ADVANCED CELL-CARCINOMA (TCC) - AN NCIC STUDY( CISPLATIN (C) ), Annals of oncology, 9, 1998, pp. 270-270
CLINICAL AND PHARMACOKINETIC (PK) RESULTS OF 4 PHASE-I STUDIES OF THE2ND-GENERATION MATRIX METALLOPROTEASE (MMP) INHIBITOR BAY-12-9566, A NONPEPTIDIC BIPHENYL INHIBITOR OF MMPS-2, MMPS-3 AND MMPS-9
Authors: SEYMOUR L GROCHOW L ECKHARDT G ERLICHMAN C HIRTE H GOEL R HUMPHREY R ELIAS I
Citation: L. Seymour et al., CLINICAL AND PHARMACOKINETIC (PK) RESULTS OF 4 PHASE-I STUDIES OF THE2ND-GENERATION MATRIX METALLOPROTEASE (MMP) INHIBITOR BAY-12-9566, A NONPEPTIDIC BIPHENYL INHIBITOR OF MMPS-2, MMPS-3 AND MMPS-9, Annals of oncology, 9, 1998, pp. 601-601
PHASE-I STUDY OF THE MATRIX METALLOPROTEASE INHIBITOR (MMPI) BAY-12-9566 IN PATIENTS WITH ADVANCED CANCER
Authors: HIRTE H GOEL R BENNETT K ELIAS I SHAH A SEYMOUR L
Citation: H. Hirte et al., PHASE-I STUDY OF THE MATRIX METALLOPROTEASE INHIBITOR (MMPI) BAY-12-9566 IN PATIENTS WITH ADVANCED CANCER, Annals of oncology, 9, 1998, pp. 286-286
PLANNED AND COMPLETED NCIC CTG TRIALS WITH BAY-12-9566, A NOVEL METALLOPROTEASE INHIBITOR (MMPI)
Authors: SEYMOUR L HIRTE H GOEL R MOORE M ELIAS I KUMOR K HUMPHREY R
Citation: L. Seymour et al., PLANNED AND COMPLETED NCIC CTG TRIALS WITH BAY-12-9566, A NOVEL METALLOPROTEASE INHIBITOR (MMPI), Annals of oncology, 9, 1998, pp. 288-288
RALTITREXED (TOMUDEX(TM)) PLUS DOXORUBICIN (DOX) IN PATIENTS WITH ADVANCED GASTRIC-CANCER - INTERIM RESULTS OF A PHASE-I DOSE-ESCALATION STUDY
Authors: BJARNASON G CHARPENTIER D WINQUIST E WONG R MATTHEWS S SEYMOUR L
Citation: G. Bjarnason et al., RALTITREXED (TOMUDEX(TM)) PLUS DOXORUBICIN (DOX) IN PATIENTS WITH ADVANCED GASTRIC-CANCER - INTERIM RESULTS OF A PHASE-I DOSE-ESCALATION STUDY, Annals of oncology, 9, 1998, pp. 459-459
A PHASE-I STUDY OF THE NOVEL L-NUCLEOSIDE ANALOG BCH-4556 GIVEN EVERY21 DAYS
Authors: BELANGER K MOORE M DIONNE J MCLEAN M PROULX L HUNT W MARSOLAIS C BAKER S WAINMAN N SEYMOUR L
Citation: K. Belanger et al., A PHASE-I STUDY OF THE NOVEL L-NUCLEOSIDE ANALOG BCH-4556 GIVEN EVERY21 DAYS, Annals of oncology, 9, 1998, pp. 601-601
GEMCITABINE (GEM) AND CISPLATIN (CIS) IS AN ACTIVE REGIMEN FOR ADVANCED TRANSITIONAL-CELL CARCINOMA (TCC) - RESULTS OF A PHASE-II STUDY
Authors: MOORE M TANNOCK I WINQUIST E TOLCHER A BENNETT K SEYMOUR L
Citation: M. Moore et al., GEMCITABINE (GEM) AND CISPLATIN (CIS) IS AN ACTIVE REGIMEN FOR ADVANCED TRANSITIONAL-CELL CARCINOMA (TCC) - RESULTS OF A PHASE-II STUDY, Annals of oncology, 9, 1998, pp. 646-646
EVALUATION OF SMANCS YRENE-CO-MALEYL-HALF-N-BUTYLATE)-NEOCARZINOSTATIN) IN TREATMENT OF INOPERABLE HEPATOCELLULAR-CARCINOMA
Authors: OLLIFF S SEYMOUR L POOLE C DETAKATS P ORME R FERRY D KERR D
Citation: S. Olliff et al., EVALUATION OF SMANCS YRENE-CO-MALEYL-HALF-N-BUTYLATE)-NEOCARZINOSTATIN) IN TREATMENT OF INOPERABLE HEPATOCELLULAR-CARCINOMA, Annals of oncology, 9, 1998, pp. 676-676
NOMENCLATURE FOR SYNTHETIC GENE DELIVERY SYSTEMS
Authors: FELGNER PL BARENHOLZ Y BEHR JP CHENG SH CULLIS P HUANG L JESSEE JA SEYMOUR L SZOKA F THIERRY AR WAGNER E WU G
Citation: Pl. Felgner et al., NOMENCLATURE FOR SYNTHETIC GENE DELIVERY SYSTEMS, Human gene therapy, 8(5), 1997, pp. 511-512
BIODEGRADABLE POLYPHOSPHAZENES FOR DRUG-DELIVERY
Authors: LEMMOUCHI Y SCHACHT E DEJARDIN S VANDORPE J SEYMOUR L
Citation: Y. Lemmouchi et al., BIODEGRADABLE POLYPHOSPHAZENES FOR DRUG-DELIVERY, Macromolecular symposia, 123, 1997, pp. 103-112
SEQUENTIAL ALPHA-INTERFERON AND TAMOXIFEN - IN-VITRO BIOLOGIC EFFECTSOF 2 GROWTH MODULATORS
Authors: SEYMOUR L BEZWODA WR
Citation: L. Seymour et Wr. Bezwoda, SEQUENTIAL ALPHA-INTERFERON AND TAMOXIFEN - IN-VITRO BIOLOGIC EFFECTSOF 2 GROWTH MODULATORS, International journal of oncology, 10(6), 1997, pp. 1277-1282
PGP AND GROWTH-FACTOR EXPRESSION IS CELL-CYCLE DEPENDENT - EXPRESSIONAND FUNCTION IS MODULATED BY SEQUENTIAL TMX AND IFN
Authors: SEYMOUR L BEZWODA WR
Citation: L. Seymour et Wr. Bezwoda, PGP AND GROWTH-FACTOR EXPRESSION IS CELL-CYCLE DEPENDENT - EXPRESSIONAND FUNCTION IS MODULATED BY SEQUENTIAL TMX AND IFN, European journal of cancer, 33, 1997, pp. 791-791
A PHASE-II STUDY OF RALTITREXED (TOMUDEX) IN PATIENTS WITH HEPATOCELLULAR-CARCINOMA
Authors: ROUGIER P DUCREUX M KERR D CARR BI FRANCOIS E ADENIS A SEYMOUR L
Citation: P. Rougier et al., A PHASE-II STUDY OF RALTITREXED (TOMUDEX) IN PATIENTS WITH HEPATOCELLULAR-CARCINOMA, Annals of oncology, 8(5), 1997, pp. 500-502
THE DEVELOPMENT AND TESTING OF A COMPETENCE-FOCUSED PSYCHIATRIC NURSING CLINICAL-EVALUATION INSTRUMENT
Authors: BONDY KN JENKINS K SEYMOUR L LANCASTER R ISHEE J
Citation: Kn. Bondy et al., THE DEVELOPMENT AND TESTING OF A COMPETENCE-FOCUSED PSYCHIATRIC NURSING CLINICAL-EVALUATION INSTRUMENT, Archives of psychiatric nursing, 11(2), 1997, pp. 66-73
THE EFFICACY AND EFFECTIVENESS OF PROCESS CONSULTATION IN IMPROVING STAFF MORALE AND ABSENTEEISM
Authors: WEIR R STEWART L BROWNE G ROBERTS J GAFNI A EASTON S SEYMOUR L
Citation: R. Weir et al., THE EFFICACY AND EFFECTIVENESS OF PROCESS CONSULTATION IN IMPROVING STAFF MORALE AND ABSENTEEISM, Medical care, 35(4), 1997, pp. 334-353
PHASE-II TRIAL OF RALTITREXED (TOMUDEX) IN ADVANCED SMALL-CELL LUNG-CANCER
Authors: WOLL PJ BASSER R LECHEVALIER T DRINGS P MANGA GP ADENIS A SEYMOUR L SMITH F THATCHER N
Citation: Pj. Woll et al., PHASE-II TRIAL OF RALTITREXED (TOMUDEX) IN ADVANCED SMALL-CELL LUNG-CANCER, British Journal of Cancer, 76(2), 1997, pp. 264-265
TOMUDEX (ZD1694) - RESULTS OF A RANDOMIZED TRIAL IN ADVANCED COLORECTAL-CANCER DEMONSTRATE EFFICACY AND REDUCED MUCOSITIS AND LEUKOPENIA (REPRINTED FROM EUROPEAN JOURNAL OF CANCER, VOL 32A, PG 1945-1954, 1995)
Authors: CUNNINGHAM D ZALCBERG JR RATH U OLVER I VANCUTSEM E SVENSSON C SEITZ JF HARPER P KERR D PEREZMANGA G AZAB M SEYMOUR L LOWERY K
Citation: D. Cunningham et al., TOMUDEX (ZD1694) - RESULTS OF A RANDOMIZED TRIAL IN ADVANCED COLORECTAL-CANCER DEMONSTRATE EFFICACY AND REDUCED MUCOSITIS AND LEUKOPENIA (REPRINTED FROM EUROPEAN JOURNAL OF CANCER, VOL 32A, PG 1945-1954, 1995), European journal of cancer, 32A, 1996, pp. 1
TOMUDEX (ZD1694) - A NOVEL THYMIDYLATE SYNTHASE INHIBITOR WITH CLINICAL ANTITUMOR-ACTIVITY IN A RANGE OF SOLID TUMORS
Authors: CUNNINGHAM D ZALCBERG J SMITH I GORE M PAZDUR R BURRIS H MEROPOL NJ KENNEALEY G SEYMOUR L
Citation: D. Cunningham et al., TOMUDEX (ZD1694) - A NOVEL THYMIDYLATE SYNTHASE INHIBITOR WITH CLINICAL ANTITUMOR-ACTIVITY IN A RANGE OF SOLID TUMORS, Annals of oncology, 7(2), 1996, pp. 179-182
A PHASE-II STUDY IN ADVANCED BREAST-CANCER - ZD1694 (TOMUDEX) A NOVELDIRECT AND SPECIFIC THYMIDYLATE SYNTHASE INHIBITOR
Authors: SMITH I JONES A SPIELMANN M NAMER M GREEN MD BONNETERRE J WANDER HE HATSCHEK T WILKING N ZALCBERG J SPIERS J SEYMOUR L
Citation: I. Smith et al., A PHASE-II STUDY IN ADVANCED BREAST-CANCER - ZD1694 (TOMUDEX) A NOVELDIRECT AND SPECIFIC THYMIDYLATE SYNTHASE INHIBITOR, British Journal of Cancer, 74(3), 1996, pp. 479-481
COMPARISON BETWEEN IMMUNOCYTOCHEMICAL AND POLYMERASE CHAIN-REACTION TECHNIQUES FOR DETECTION OF ESTROGEN-RECEPTOR AND TRANSFORMING GROWTH-FACTOR-BETA IN BREAST-CANCER
Authors: AMOILS KD SEYMOUR L BEZWODA WR
Citation: Kd. Amoils et al., COMPARISON BETWEEN IMMUNOCYTOCHEMICAL AND POLYMERASE CHAIN-REACTION TECHNIQUES FOR DETECTION OF ESTROGEN-RECEPTOR AND TRANSFORMING GROWTH-FACTOR-BETA IN BREAST-CANCER, British Journal of Cancer, 73(10), 1996, pp. 1255-1259
BIOMEDICAL APPLICATIONS OF DEGRADABLE POLYPHOSPHAZENES
Authors: SCHACHT E VANDORPE J DEJARDIN S LEMMOUCHI Y SEYMOUR L
Citation: E. Schacht et al., BIOMEDICAL APPLICATIONS OF DEGRADABLE POLYPHOSPHAZENES, Biotechnology and bioengineering, 52(1), 1996, pp. 102-108
INFLUENCE OF TUMOR ESTROGEN CONCENTRATION ON PROGNOSIS IN BREAST-CANCER - STUDIES IN PREMENOPAUSAL AND POSTMENOPAUSAL PATIENTS OF DIFFERENTETHNIC-GROUPS
Authors: BEZWODA WR DANSEY R SEYMOUR L MANSOOR N
Citation: Wr. Bezwoda et al., INFLUENCE OF TUMOR ESTROGEN CONCENTRATION ON PROGNOSIS IN BREAST-CANCER - STUDIES IN PREMENOPAUSAL AND POSTMENOPAUSAL PATIENTS OF DIFFERENTETHNIC-GROUPS, Breast, 4(4), 1995, pp. 259-266
HIGH-DOSE CHEMOTHERAPY WITH HEMATOPOETIC RESCUE AS PRIMARY-TREATMENT FOR METASTATIC BREAST-CANCER - A RANDOMIZED TRIAL
Authors: BEZWODA WR SEYMOUR L DANSEY RD
Citation: Wr. Bezwoda et al., HIGH-DOSE CHEMOTHERAPY WITH HEMATOPOETIC RESCUE AS PRIMARY-TREATMENT FOR METASTATIC BREAST-CANCER - A RANDOMIZED TRIAL, European journal of cancer, 31A, 1995, pp. 349-349
TOMUDEX (ZD1694) - RESULTS OF A RANDOMIZED TRIAL IN ADVANCED COLORECTAL-CANCER DEMONSTRATE EFFICACY AND REDUCED MUCOSITIS AND LEUKOPENIA
Authors: CUNNINGHAM D ZALCBERG JR RATH U OLVER I VANCUTSEM E SVENSSON C SEITZ JF HARPER P KERR D PEREZMANGA G AZAB M SEYMOUR L LOWERY K ACKLAND SP BASSER RL CLARKE SJ GOLDSTEIN D GREEN MD GRYGIEL JJ MCKENDRICK JJ MILLWARD MJ OLVER IN TATTERSALL MHN THOMSON DB JAKESZ R BUSET M TUENI EA VANCUTSEM EJD BAUER J BESKA F ADENIS A BRUNET R FRANCOIS E PAILLOT B ROUGIER P FINK UFW KNUTH KRA KOENIG HJ BOHME MWJ WANDER HE AMADORI D FRASSINETI L COCCONI G PASSALACQUA R FRIGERIO F BARNI S LUPORINI G LABIANCA R MARINI G ZANIBONI A KLEPP O TVEIT KM WIST E CANDEIAS OFR GOUVEIA JGP MARQUES JCN OLIVEIRA JML CAVALLI F DELMORE GD GOEDHALS L VOROBIOF DA ESTEVE AAI AGUILAR EA TORRES AA RUIPEREZ AC RUBIO ED SUREDA BM MANGA GP ALFONSO PG GUSTAVSSON B JEPPSON B MALMBERG M STARKHAMMAR H SVENSSON JH KEIZER HJ SCHORNAGEL JH OBRIEN M HARPER PG KERR DJ SCARFFE JH TYRELL CJ
Citation: D. Cunningham et al., TOMUDEX (ZD1694) - RESULTS OF A RANDOMIZED TRIAL IN ADVANCED COLORECTAL-CANCER DEMONSTRATE EFFICACY AND REDUCED MUCOSITIS AND LEUKOPENIA, European journal of cancer, 31A(12), 1995, pp. 1945-1954
A PHASE IN STUDY OF TOMUDEX IN RELAPSED EPITHELIAL OVARIAN-CANCER
Authors: GORE ME EARL HM CASSIDY J TATTERSALL M MANSI J SEYMOUR L AZAB M
Citation: Me. Gore et al., A PHASE IN STUDY OF TOMUDEX IN RELAPSED EPITHELIAL OVARIAN-CANCER, Annals of oncology, 6(7), 1995, pp. 724-725
Risultati: 1-25 | 26-38